Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than oncology.
Vertex Pharmaceuticals has announced meaningful results from two Phase II studies of its therapeutic VX-548. It is a non opioid pain medication that promises results.
When Sekar Kathiresan’s brother unexpectedly died from a heart attack, he changed the course of his life to found a company with a novel medicine that may prevent them.
Ginkgo Bioworks reported its 2021 financials today, and the $1.7 billion of stock-based compensation caught everyone’s attention.
Taysha Gene Therapies announced that it will focus its efforts on clinical programs targeting Rett Syndrome and giant axonal neuropathy (GAN), resulting in a 35% reduction in its workforce.
CAR-T cell therapy is still a time-consuming and expensive process. But researchers may have just solved the turnaround-time challenge for CAR-T.
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson’s pay had a drop of about 3.7%, according to the company’s annual filing.
Myeloid Therapeutics has signed an exclusive collaboration deal with Prime Medicine to leverage both companies’ technologies and discover cancer and autoimmune diseases treatments.
The man who many consider the father of synthetic insulin treatment for diabetes, as well as a founder of modern biotechnology- Dr. Arthur Riggs - died this week at the age of 82.
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity,
The U.S. FDA placed a partial hold on CytoDyn’s HIV program and a full clinical hold on its COVID-19 program in the U.S.
It’s a promising day for advanced ovarian cancer research as two biopharma companies achieved positive results. Here’s what you need to know about research.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations